when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Oncology · news · pharmadog

← back to Oncology

News · Oncology

1,498 stories

Sep 3, 26Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—againbiospace

Sep 3, 26STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and morestat

Sep 3, 26Akeso, Summit cancer drug confirms lung cancer survival benefitbiopharma dive

Sep 3, 26GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapybiospace

Sep 3, 26Psilocybin proves promising in neuropathic pain mouse studyfiercebiotech

Sep 3, 26Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ dealfiercebiotech

Sep 3, 26Replimune’s melanoma drug would have been rejected again if not for senior CBER officialbiospace

Sep 3, 26Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialendpoints

Sep 3, 26STAT+: Abivax has still not been acquired. What’s going on?stat

Sep 3, 26GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontendpoints

Sep 3, 26Breaking borders: Building biotech scale in Beneluxbiospace

Sep 3, 26AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialfiercebiotech

Sep 3, 26GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetfiercebiotech

Sep 3, 26Capricor, Replimune illustrate why FDA must listen to rare disease specialistsbiospace

Sep 3, 26Recon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drugraps

Sep 2, 26FDA raises bar for foreign site inspections as China trials surgebiospace

Sep 2, 26Novartis CAR-T deaths raise questions over acceptable autoimmune riskendpoints

Sep 2, 26Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study haltsbiopharma dive

Sep 2, 26CBER official overruled review team's rejection of new Replimune melanoma drugendpoints

Sep 2, 26Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide divisionfiercebiotech

Sep 2, 26Teva claims success in celiac study; BioMarin, Ascendis settle patent disputebiopharma dive

Sep 2, 26STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and morestat

Sep 2, 26TScan axes 75% of workforce to make room for solid tumor programsfiercebiotech

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Sep 2, 26Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsbiospace

Sep 1, 26STAT+: House votes to temporarily block Trump plan to politicize federal grantsstat

Sep 1, 26Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?fiercebiotech

Sep 1, 26Mid-cap biotechs join Trump’s latest round of drug pricing dealsbiopharma dive

Sep 1, 26Novartis says MS pill succeeds in two large studiesbiopharma dive

Sep 1, 26Roche finds another oncology gem in Asia with $1.5B B cell disease partnershipbiospace

← prevpage 15 of 50next →